Skip to content

Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in At-risk Patients

Prosthesis Infection and One-step Exchange: Pretreatment by Targeted Antibiotic Therapy in

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03848091
Enrollment
13
Registered
2019-02-20
Start date
2016-04-01
Completion date
2018-01-01
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Resistant Infection, Prosthetic Joint Infection

Keywords

bone and joint infection, Antibiotic pretreatment

Brief summary

One-step exchange arthroplasty is more and more used in the treatment of chronic infections, especially in patients at risk anesthetic. This strategy is not recommended in patients infected with multidrug-resistant organisms or difficult to treat because of a risk of bacterial persistence on the new implant. Antibiotic pretreatment by a narrow-spectrum molecule and for which resistance acquisition is difficult might be of interest to try to reduce the inoculum and avoid contamination of the new implant.

Interventions

OTHERAntibiotic pretreatment

a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* patients having had a antibiotic pretreatment targeted before a one step exchange arthroplasty

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Rate of Treatment FailureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionTreatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Secondary

MeasureTime frameDescription
rate of use of this strategyOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptiondescriptions of patients managed with this strategy
rate of bacteria responsible for infectionOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionbacterial epidemiology

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026